ALPN News and Press, Alpine Immune Sciences Inc. From 05/11/23

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2023. “So far this year, we have ac...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today announced that the Company will participate in the 2023 Bank of America Securities Healthcare Conference. ...

2023-03-29 07:37:25 ET Summary Last year, ALPN ditched its lead program after a second patient death in a CD28 molecule, a previously notorious pathway. ALPN has started all over again, with backing from a few big pharma. They do have a decent cash runway. Alpine Imm...

2023-03-23 19:41:05 ET Alpine Immune Sciences, Inc. (ALPN) Q4 2022 Earnings Conference Call March 23, 2023 4:30 PM ET Company Participants Temre Johnson - SD, IR Mitchell Gold - Executive Chairman, CEO Stanford Peng - President, Head of R&D Paul Rickey - ...

2023-03-23 16:08:28 ET Alpine Immune Sciences press release ( NASDAQ: ALPN ): Q4 GAAP EPS of -$0.41 misses by $0.14 . Revenue of $2.78M (-38.6% Y/Y) misses by $8.18M . For further details see: Alpine Immune Sciences GAAP EPS of -$0.41 misses by $0.14, rev...

RUBY-3, a basket study of povetacicept in autoimmune glomerulonephritis, has initiated patient enrollment; RUBY-4, a basket study of povetacicept in autoimmune cytopenias, targets initiation in Q2 2023 Initial data from both basket studies are anticipated by the end of 2023 ...

2023-03-22 17:35:34 ET Alpine Immune Sciences ( NASDAQ: ALPN ) is scheduled to announce Q4 earnings results on Thursday, March 23rd, after market close. The consensus EPS Estimate is -$0.26 (+50.0% Y/Y) and the consensus Revenue Estimate is $10.96M (+141.9% Y/Y). For...

2023-03-22 17:35:12 ET Major earnings expected after the bell on Thursday include: Ideanomics ( IDEX ) Planet 13 Holdings ( OTCQX:PLNHF ) Spruce Power Holding Corporation ( SPRU ) Heron Therapeutics ( HRTX ) ADMA Biologics ( ADMA ) For further...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present posters at the American Society for Clinical Pharmacology & Therapeutics (ASCPT) Annual Meeting and ...

Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, will present an ePoster with an oral presentation at the American Academy of Dermatology (AAD) Annual Meeting, highli...